Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWJ1351 PK and Safety Study in Healthy Males
NCT03753477Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OLOMAX in hypertension (HTN) and hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Started Dec 2017; status: completed.
02
Drugs
OLOMAX
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT03753477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753477.